國家衛生研究院 NHRI:Item 3990099045/7733
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 12189/12972 (94%)
造访人次 : 955454      在线人数 : 728
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻
    主页 ‧ 登入 ‧ 上传 ‧ 说明 ‧ 关于NHRI ‧ 管理 到手机版


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/7733


    题名: Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: A prospective study
    作者: Hsu, C;Tsou, HH;Lin, SJ;Wang, MC;Yao, M;Hwang, WL;Kao, WY;Chiu, CF;Lin, SF;Lin, J;Chang, CS;Tien, HF;Liu, TW;Chen, PJ;Cheng, AL
    贡献者: National Institute of Cancer Research;Division of Biostatistics and Bioinformatics
    摘要: Fatal hepatitis B virus (HBV) reactivation in lymphoma patients with 'resolved' HBV infection (HBsAg-negative and anti-HBc-positive) has been reported but the true incidence and severity remain unclear. From June 2009 to December 2011, 150 newly diagnosed lymphoma patients with resolved HBV infection who were to receive rituximab-CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone)-based chemotherapy were prospectively followed. HBV DNA was checked at baseline, at the start of each cycle of chemotherapy, and every 4 weeks for 1 year after completion of the rituximab-CHOP chemotherapy. Patients with documented HBV reactivation were treated with entecavir at a dosage of 0.5 mg/d for 48 weeks. HBV reactivation was defined as a greater than 10-fold increase in HBV DNA compared with previous nadir levels, and hepatitis flare was defined as a greater than 3-fold increase in ALT that exceeded 100 IU/L. The incidence of HBV reactivation and HBV-related hepatitis flares was 10.4 and 6.4 per person-year, respectively. Severe HBV-related hepatitis (ALT > 10 fold of upper normal limit) occurred in 4 patients despite entecavir treatment. Patients with hepatitis flare exhibited significantly higher incidence of re-appearance of HBsAg after HBV reactivation (100% vs. 28.5%; P=.003). Our data indicates that in lymphoma patients with resolved HBV infections, chemotherapy-induced HBV reactivation is not uncommon but can be managed with regular monitoring of HBV DNA and prompt antiviral therapy. Serological breakthrough (i.e., re-appearance of HBsAg) is the most important predictor of HBV-related hepatitis flare.
    日期: 2014-06
    關聯: Hepatology. 2014 Jun; 59(6):2092-2100
    Link to: http://dx.doi.org/10.1002/hep.26718
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0270-9139&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000337567100010
    Cited Times(Scopus): http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84901591515
    显示于类别:[劉滄梧] 期刊論文
    [鄒小蕙] 期刊論文

    文件中的档案:

    档案 描述 大小格式浏览次数
    PUB24002804.pdf604KbAdobe PDF799检视/开启


    在NHRI中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈